Yeah, there's a LOT of chess being played here- and Josh better damn well deliver some goods by earnings time.
I still believe they get a pretty substantial jump in top-line revenues from selling tests. How long it lasts- unknown, but at least a decent one or two time bump.
Healight could be pretty damn big if they can pull it off- the fact they are already at "First article" delivered via that PR means they're moving real fast on it. It's not a drug, it's a "medical device" and may be able to get FDA approval on just a 510K device track. THAT and fast-track if it can be proven useful in extreme COVID cases which is going to be with us for some time.
IF they get an FDA approval on Healight- all bets are off as to where the market cap can go on this baby and likely AYTU would be acquired fairly quickly at that point- treatment of intubated patients of all sorts of upper airway issues across a broad spectrum of patient types and problems. Disposables for re-sale after the base unit- as it will need throw-away inserts that go down the airway tube, etc. REAL good concept if they can make it work and get ANY FDA use.
Financials are going to be the key next up- cash, cash use, top-line revenues, health of the balance sheet. ALL THE USUAL STUFF.
Joshy boy has gone pretty damn quiet- and I don't know if that "Test partner distribution" PR is a net positive or showing lack of selling tests? It's a wobbler?
A LOT of their existing sales channels for their existing product lines were built using that exact same model- the partner channels thing. Josh and his brother seem to like they model and know how to play it and did it with the prior company they sold for a cool $billion or so.
We'll see- gonna be some PIVOTAL KEY times around the bend in the next 30 days or so.